Warsaw - Delayed Quote PLN

Ryvu Therapeutics S.A. (RVU.WA)

32.95

-1.00

(-2.95%)

At close: April 29 at 5:03:11 PM GMT+2

Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update.

PR Newswire 5 months ago

9Y4.F

9Y4.DU

9Y4.SG
Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents four posters with clinical and preclinical data from RVU305 (MTA-cooperative PRMT5 inhibitor), WRN program, ONCO Prime, and RVU120 at the 2024 EORTC-NCI-AACR Symposium (ENA), October 23-25, Barcelona, Spain.

PR Newswire 6 months ago

9Y4.DU

9Y4.F

9Y4.SG
Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, will present four posters with clinical and preclinical data from RVU120 (CDK8/19 inhibitor), RVU305 (MTA-cooperative PRMT5 inhibitor), WRN and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium (ENA), October 23-25, Barcelona, Spain.

PR Newswire 6 months ago

9Y4.SG

9Y4.DU

9Y4.F
Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, will present its ONCO Prime drug discovery platform at the 6th Annual RAS-Targeted Drug Development Summit, a leading global end-to-end RAS therapies forum, which will take place on September 24-26 in Boston, MA.

PR Newswire 7 months ago

9Y4.F

9Y4.SG

9Y4.DU
Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, presents clinical and preclinical data from RVU120 at the 2024 European Hematology Association Congress (EHA), June 13-16, Madrid, Spain.

PR Newswire 10 months ago

9Y4.SG

9Y4.F
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the first quarter, ended March 31, 2024, and provided a corporate update.

PR Newswire 11 months ago

9Y4.DU

9Y4.SG

9Y4.F

Performance Overview

Return	RVU.WA	MSCI WORLD (^990100-USD-STRD)
YTD	-14.42%	-1.87%
1-Year	-33.16%	--
3-Year	-15.51%	+27.52%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ryvu Therapeutics S.A. (RVU.WA)

Ryvu Therapeutics Reports 2024 Q3 Financial Results and Provides Corporate Update

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update

Performance Overview